Avadel Pharmaceuticals PLC (AVDL)
$10.39 -$0.23 (-2.17%) 4:38 PM 12/13/24
NASDAQ | $USD | Drug Manufacturers - Specialty & GenericStock Data
-
Market Cap
$1.27B -
Day's Range
$10.38 - $10.64 -
Volume
1,291,528 -
52 Week Low / High
$9.41 - $19.09 -
PE Ratio
- -
PEG Ratio
0.07 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 7
- Strong Buy
- 3
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $19.89
- Target Price
Company News
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Pharmaceuticals plc – Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data underscore that alerting agents alone are often insufficient for...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Pharmaceuticals plc – Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data underscore that alerting agents alone are often insufficient for...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
-
Avadel Pharmaceuticals plc -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in pediatric narcolepsy patients 7 years and olde...
-
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz — Oct 18th, 2024
Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven yea...
Portfolio
Comprised of 1 portfolios